Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cisplatin/vinblastine - Intensity Therapeutics

Next Previous
Drug Profile

Cisplatin/vinblastine - Intensity Therapeutics

Alternative Names: Cisplatin/vinblastine sulfate; INT 230-6; PORT-1

Latest Information Update: 03 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Intensity Therapeutics
  • Developer Intensity Therapeutics; Ottawa Hospital Research Institute
  • Class Antineoplastics; Platinum complexes; Small molecules; Vinca alkaloids
  • Mechanism of Action DNA cross linking agents; DNA synthesis inhibitors; Mitosis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Soft tissue sarcoma
  • Phase II Breast cancer; Solid tumours; Triple negative breast cancer
  • Preclinical Neurofibrosarcoma

Most Recent Events

  • 24 Mar 2026 Intensity Therapeutics has one patent pending in USA
  • 12 Mar 2026 Efficacy and Adverse events data from a phase II INVINCIBLE-4 trial in Triple-negative breast cancer released by Intensity Therapeutics
  • 13 Jan 2026 Intensity Therapeutics plans a phase III trial for Neoadjuvant triple-negative breast cancer (Combination-therapy)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top